Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above
CompanyDrug

Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its wholly‑owned subsidiary, Xiamen Innovax Biotech Co., Ltd., has received the Drug Clinical Trial Approval Notice from China's National…

Sansure Biotech's Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens
CompanyMedical Device

Sansure Biotech’s Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Guangdong True Health Medical's Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World's First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model
Company

Guangdong True Health Medical’s Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World’s First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors
CompanyDrug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

- Advertisement -
Ad image
Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1
CompanyDeals

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Alexion's Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca's Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle
CompanyDrug

Alexion’s Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca’s Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle

Novartis' Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology
CompanyDrug

Novartis’ Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer
CompanyDrug

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer

FDA Accepts Alexion's BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+
CompanyDrug

FDA Accepts Alexion’s BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
CompanyDrug

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

Roche Opens Genentech Innovation Center Boston at Harvard's Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D
Company

Roche Opens Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus – New US Hub for Cardiovascular, Renal and Metabolism R&D

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
CompanyDrug

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

Show More